June 17, 2019

Dear Friend of TAG:

I’m thrilled to share with you TAG’s 2018 Annual Report. Here you will see how TAG’s effective, tenacious activism has battled with a political climate replete with obstacles and barriers and destructive policies to defend and expand U.S. funding for international and domestic efforts to fight HIV, hepatitis C virus (HCV), and tuberculosis (TB).

TAG won significant victories in 2018, including expanded support for research conducted by the U.S. National Institutes of Health, the domestic AIDS Drug Assistance Programs and the international efforts to fight AIDS and TB, the endorsement by the World Health Organization and the United Nations General Assembly of ambitious targets for TB research and programs, the launch of a historic HCV elimination strategy and task force by New York State, and measurable progress against the HIV and TB epidemics in New York City and New York State.

Your support makes all our work possible. In the coming year we’ll continue to fight to build evidence, programs, strategies, and alliances to bring the end of these three epidemics closer than ever. From the bottom of our hearts, I and everyone on TAG’s board and staff – and on behalf of the communities our advocacy serves to preserve their health and lives – thank you for all the work that your support makes possible!

Yours truly,

Barbara Hughes
President, Board of Directors
TAG’s 2018 Research in Action Awards took place on November 15 at Slate in New York City, and honorees were: Masha Gessen; Margaret Hamburg, MD; Joy Tomchin; and Jenna Wolfe, who received a Lifetime Friend of TAG award. The event honors activists, scientists, philanthropists, and creative artists who have made contributions to the fight against HIV, tuberculosis, and hepatitis C virus. Resources raised at RIAA provide vital support for TAG’s programs throughout the year.

Event co-host Ann Northrop gave a moving reading of Zoe Leonard’s "I want a president."

Honoree Masha Gessen, accepting her award via Skype.

UNITED’s Jim Aquino and Bob Bronzo talked about why they and their friends, UNITED, donate to TAG.

Honoree Peggy Hamburg on stage.

Paul Katz of the Marta Heflin Foundation (an RIAA sponsor), with Barbara Hughes, TAG Board President.

TAG ED Mark Harrington, with honoree Joy Tomchin.
In 2018, TAG furthered Ending the Epidemic (EtE) success in New York. Recent reports from New York City and State showed that new HIV infections are beginning to decline due to the state’s EtE strategy. To share best practices and lessons learned from New York with the rest of the country and world, TAG launched a series of online EtE modules. In partnership with Housing Works, TAG created the first EtE University, at which representatives from the hard-hit southern United States convened to learn and plan for launching EtE plans in their jurisdictions. This support helped spur EtE movements in Alabama, Louisiana, and Nashville, Tennessee. The Act Now, End AIDS coalition, which TAG co-convenes, drove the drafting of a national EtE plan that launched on World AIDS Day 2018, and which will underpin much important advocacy and accountability for ongoing U.S. government efforts to combat HIV around the country.

TAG’s role leading evidence-based advocacy around HIV basic science, vaccines, and cure placed our work at the forefront of many important discussions in 2018. Richard Jefferys’ longstanding work on gene editing poised TAG to respond quickly, knowledgeably, and powerfully to troubling news: TAG decried the report from researcher He Jiankui of twins born from embryos whose genes he had unethically edited using CRISPR technology for the HIV co-receptor CCR5.

TAG delved into implications of HIV cure-related trials involving interruptions of antiretroviral therapy for a research summit, to ensure community perspectives were incorporated. TAG advocated for appropriate therapeutic interventions for people who, despite HIV treatment, still have poor immune reconstitution. Our HIV Cure Clinical Trials website listing, updated monthly, has become a central resource for researchers and partners seeking information on cure studies and their results.

TAG’s deep understanding of science also underpins our effective policy and anti-discrimination work.

Armed with the knowledge of the myriad ways to effectively treat and prevent HIV, TAG’s Jeremiah Johnson led an advocacy campaign to confront the Peace Corps regarding its poor policies on HIV treatment, care, and prevention. The Peace Corps had discriminated against Jeremiah in 2008 when it kicked him out of his Peace Corps posting in Ukraine for testing positive for HIV. That the same discrimination would resurface a decade later, with two volunteers ejected in 2018, catalyzed a successful campaign by Jeremiah and other U.S. HIV policy organizations. One volunteer resumed service; the other has decided to stay in the U.S. for the time being. The Peace Corps committed to increase the list of host countries where HIV positive volunteers can serve, and opened the lines of communication for ongoing discussions on ways to improve their HIV policies.

In 2018, TAG’s HIV team published the following publications:

- TAG Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy
- Community Recommendations for Clinical Research Involving Antiretroviral Treatment Interruptions in Adults
- The Antiretroviral Pipeline
- The HIV PrEP and Microbicides Pipeline
- The HIV Vaccines, Passive Immunization, and Antibody Gene Transfer Pipeline
- The Research Toward a Cure and Immune-Based Therapies Pipeline
- Keeping an Eye on Intellectual Property Issues in HIV Cure and Prevention Research (TAGline December 2018)
- Bend the Curves: Activism and the Elimination of HIV, HCV, and TB (TAGline April 2018)
- The Usual Suspects: Common Challenges for EtE Planning and Implementation in Emerging Jurisdictions (TAGline April 2018)
- New York State EtE Campaign Update: Successes & Challenges (TAGline April 2018)
- The Role of Vaccines and Cures in HIV Elimination (TAGline April 2018)
HEPATITIS C VIRUS (HCV) PROJECT

Among TAG’s biggest victories in 2018 was advocacy to secure Governor Cuomo’s commitment to eliminate HCV in New York State. The result of a lengthy budget and policy advocacy campaign led by TAG’s Annette Gaudino, this commitment made New York the first state in the nation to commit to ending HCV. Governor Cuomo’s announcement included a two-year commitment to quadruple program funding for HCV, and the commission of a statewide HCV Elimination Task Force, to which Annette was appointed. In New York City, TAG advocated successfully for increased funding for peer HCV prevention, testing, linkage to care, and treatment support.

With the advent of simple, highly effective cures for HCV, elimination can and should be the goal everywhere. But poor access to screening and testing remains a barrier. Awareness, improved treatment and diagnostics literacy, and capacity building in advocacy are key to scaling up of HCV diagnosis and treatment access. As such, TAG – with new support from the Foundation for Innovative New Diagnostics (FIND) – launched an HCV diagnostics advocacy training and support project. Bryn Gay is leading this work, which includes targeted trainings in Georgia and Malaysia, and technical assistance for activists in Cameroon, India, Myanmar, and Vietnam.

Our global HCV work includes broader community mobilization to address structural barriers to care.

Recognizer the importance of addressing the disproportionate burden of HCV in migrant communities, TAG co-convened with the European African Treatment Advocates Network and other migrant-focused organizations the European African HIV and HCV Community Summit. Held just before the AIDS 2018 conference in Amsterdam, the Summit developed strategies to make the best treatment and diagnostics accessible for all, and to ensure that national elimination plans include policies supporting the health and rights of migrants.

To support this work, TAG’s HCV team published the following publications:

- Training Manual for Treatment Activists, Hepatitis C Virus & Coinfection with HIV (available in English, French, and Spanish)
- The HCV Diagnostics Pipeline
- The HCV Treatment Pipeline
- Fierce Activism from the Global Access to Medicines (A2M) Movement: Reflections on Recent Success (TAGline December 2018)
- Getting Rid of the Boogeyman: The Reality of Prescription Drug Price Controls (TAGline December 2018)
- Pharma Lies, People Die: Myth-Busting Fact Sheet on Medicine Development and Pricing (TAGline December 2018)
- It’s up to You, New York: Moving towards HCV Elimination in the Empire State (TAGline April 2018)
- Global HCV Elimination Targets and Challenges: An Interview with Andrew Hill (TAGline April 2018)

TUBERCULOSIS (TB) PROJECT

2018 was a momentous year for the global fight against tuberculosis. The United Nations General Assembly held its first-ever High-Level Meeting on TB. TAG’s work in the lead up to the event centered on securing commitments for investing in TB research and development (R&D) and equitable access to the fruits of those investments. TAG’s work continued to focus on neglected populations, including people with HIV and TB co-infection, and children – who make up 10% of TB cases globally, yet are too seldom included in either research or programs. Erica Lessem organized and Mike Frick presented at a briefing for UN missions on TB R&D. Suraj Madoori organized meetings.
TAG’s TB and policy teams advanced a novel approach laying out “fair share” targets by which each country dedicates 0.1% of its overall spending on research to TB research in particular, which would close the global TB R&D funding gap. The resultant Political Declaration from the High-Level Meeting itself endorsed a goal of ensuring that each country contributes appropriately to TB R&D. Thanks to Lindsay McKenna’s tireless advocacy in collaboration with partners, pediatric commitments made it into the Political Declaration.

TAG’s TB work draws upon Mike Frick’s extensive work analyzing TB R&D investments over more than a decade and his efforts to advance the human right to enjoy the benefits of scientific progress and its applications. In 2018, the latter featured several submissions to UN bodies, including a presentation to the UN Committee on Economic, Social and Cultural Rights, which will inform the first authoritative interpretation of the right to science, expected later in 2019.

While New York City hosted the UN General Assembly meeting, it was also abuzz with its own response to a growing local TB problem. After over a decade of chronic under-investment in New York City’s TB response, exacerbated by a fresh budget cut from New York State, TB cases in New York City grew substantially in 2017 for the first time in two decades. This worrying trend jumpstarted TAG into action to quickly convene an activist coalition of New York based organizations working on immigration, homelessness, and other health and vulnerable population issues. This coalition rallied political and media attention, and resulted in restoring $2.4 million in funding for New York City’s TB program, which allowed for reinstatement of staff positions and for clinics to remain open.

2018 also saw the culmination of years of advocacy to encourage the uptake of newer, more effective, less toxic treatment options for TB. TAG and collaborators successfully encouraged the World Health Organization to update its drug-resistant TB guidelines, resulting in recommendations for a safer, more effective standard of care based on newer drugs including bedaquiline. While the recommendations still require improvement, they are nonetheless a major step forward in ensuring people will no longer be subjected to painful injections or hearing loss from toxic, less effective older TB medicines. To help promote uptake of bedaquiline in the U.S., TAG, the National TB Controllers Association, and Johns Hopkins University led a successful campaign to reduce access barriers, including improvements to the patient assistance program to ease free access, and a commitment from the manufacturer for packaging better suited to the needs of TB programs and patients.

TAG’s prolific TB team issued multiple publications to advance these advocacy initiatives:

- **Know Your Rights Guide: Tuberculosis Prevention, Diagnosis, and Treatment** (available in nine languages)
- **Is Shorter Better? Understanding the Shorter Regimen for Treating Drug Resistant Tuberculosis**
- **The Vital Role of Research for TB Elimination**
- **An Activist’s Guide to Bedaquiline**
- **Reality Check: The Price of Bedaquiline**
- **Tuberculosis Research Funding Trends, 2005-2017**
- **Funding for TB Research – Recent Momentum Must Inspire Bold Commitments**
- **The Pediatric Tuberculosis Pipeline**
  - The Tuberculosis Diagnostics Pipeline for Children
  - The Tuberculosis Prevention Pipeline for Children
  - The Tuberculosis Treatment Pipeline for Children
- **The Tuberculosis Prevention Pipeline**
- **A Pharma View on Delinkage and New Models for Biomedical Innovation: An Interview with Marc Destito From Otsuka Pharmaceutical** (TAGline December 2018)
- **The United Nations’ Back Yard: TB Elimination in New York State and the U.S.** (TAGline April 2018)
- **From Moscow to New York and Beyond: The Future of Tuberculosis Research and Development** (TAGline April 2018)
TAG’s U.S. and Global Health Policy team supported and were instrumental to advancing many of the previously mentioned initiatives. With coordination from Suraj Madoori, TAG staff wrote many sections of the above-mentioned community-driven National EtE Plan to reflect needed priorities to address HIV, as well as HCV and TB.

Drug pricing and access was central to TAG's work, and remains so with an explosion of political attention in 2019. In 2018, TAG helped prepare allies for this work by creating and leading many sessions at the Affordable Medicines Now Conference, which was the first conference dedicated to providing a space for U.S.-based access-to-medicines activists to tackle issues from intellectual property abuses to extortionate drug pricing. TAG ramped up its legislative engagement to promote access and lower drug prices: Suraj Madoori and external partners successfully fended off an amendment to the Pandemics and All-Hazards Preparedness Act known as the Re-Valuing Anti-Microbial Products Act of 2018, which would have created transferable monopolies for developers of antimicrobials, while failing to provide any access requirements for resulting products.

Another legislative advance in 2018 was the inclusion of TB priorities in the Health Equity and Accountability Act by the Congressional Black Caucus, Hispanic Caucus, and Asian Pacific Islander Caucus. TAG and partners secured a $15 million increase for USAID’s TB program for fiscal year 2018 – the biggest federal TB increase in years, and fended off the President’s cuts for domestic HIV and viral hepatitis. TAG protected funding for U.S. Centers for Disease Control and Prevention (CDC)’s domestic TB elimination, while advancing the Comprehensive TB Elimination Act, which would authorize funding for five years for the CDC’s domestic TB response and global TB research.

TAG was active at resisting mounting threats to foreign-born Americans, which would undermine their human rights as well as their and the broader public’s health. Annette Gaudino and Erica Lessem spent a night in jail for civil disobedience in response to a draft rule that would dramatically redefine a “public charge,” deterring many from seeking key treatment and prevention for HIV, HCV, TB, and other health conditions out of fear of becoming ineligible for immigration status adjustments (e.g., getting a green card). TAG joined many community groups in opposing the addition of a citizenship question to the Census; TAG’s public comment explained how such an addition could discourage participation and lead to inequities in the allocation of federal resources.

Drug pricing and access was central to TAG’s work, and remains so with an explosion of political attention in 2019.

Some key TAG policy publications from 2018 that advanced our work include:

- United to End Tuberculosis: Key Asks for the U.S. from TB Stakeholders and Communities
- Ending Exemptions from the Pediatric Research Equity Act (PREA)
- Beyond Declarations: Lessons from the UN High-Level Meeting on TB on Building and Transforming Political Will into Real Access to Medicines (TAGline December 2018)
- In a State of Disunion: HIV, TB, and HCV Elimination Policies and Priorities Under the Trump Administration (TAGline April 2018)
### Balance Sheet

#### Assets

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,534,231</td>
<td>$1,949,112</td>
</tr>
<tr>
<td>Unconditional Promises to Give</td>
<td>1,216,871</td>
<td>1,549,894</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>1,139</td>
<td></td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>31,594</td>
<td>25,384</td>
</tr>
<tr>
<td>Donated artwork</td>
<td>439,739</td>
<td>414,500</td>
</tr>
<tr>
<td>Security deposit</td>
<td>72,463</td>
<td>72,463</td>
</tr>
<tr>
<td>Property and equipment - net</td>
<td>26,728</td>
<td>25,974</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$3,322,765</strong></td>
<td><strong>$4,037,327</strong></td>
</tr>
</tbody>
</table>

#### Liabilities and Net Assets

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$25,396</td>
<td>$25,660</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>$42,520</td>
<td>$55,069</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>67,916</strong></td>
<td><strong>80,729</strong></td>
</tr>
<tr>
<td>Without donor restrictions</td>
<td>1,736,034</td>
<td>1,907,539</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>1,518,815</td>
<td>2,049,059</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>3,254,849</strong></td>
<td><strong>3,956,598</strong></td>
</tr>
</tbody>
</table>

**Total Liabilities and Net Assets**

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$3,322,765</strong></td>
<td><strong>$4,037,327</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Statement of Cash Flows

#### Cash Flows from Operating Activities

Adjustments to reconcile increase (decrease) in net assets to net cash used by operating activities:

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>($701,749)</td>
<td>$1,438,463</td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>10,873</td>
<td>9,432</td>
</tr>
<tr>
<td>(Increase) decrease in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unconditional promises to give</td>
<td>333,023</td>
<td>(1,476,023)</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>(1,139)</td>
<td></td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>(6,210)</td>
<td>6,442</td>
</tr>
<tr>
<td>Donated artwork</td>
<td>(25,239)</td>
<td>(10,000)</td>
</tr>
<tr>
<td>Increase (decrease) in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>(264)</td>
<td>(3,853)</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>(12,549)</td>
<td>10,499</td>
</tr>
<tr>
<td><strong>Net Cash Used by Operating Activities</strong></td>
<td>(403,254)</td>
<td>(25,040)</td>
</tr>
</tbody>
</table>

#### Cash Flows from Investing Activities

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acquisition of property and equipment</td>
<td>(11,627)</td>
<td>(4,970)</td>
</tr>
<tr>
<td>Proceeds from sales of fixed assets</td>
<td></td>
<td>434</td>
</tr>
<tr>
<td><strong>Net Cash Used by Investing Activities</strong></td>
<td>(11,627)</td>
<td>(4,536)</td>
</tr>
</tbody>
</table>

#### Net decrease in cash and cash equivalents

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>(414,881)</td>
<td>(29,576)</td>
<td></td>
</tr>
</tbody>
</table>

#### Cash and cash equivalents, beginning of year

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,949,112</td>
<td>1,978,688</td>
<td></td>
</tr>
</tbody>
</table>

#### Cash and Cash Equivalents - End of Year

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$1,534,231</strong></td>
<td><strong>$1,949,112</strong></td>
<td></td>
</tr>
</tbody>
</table>
### Statement of Activities

#### Revenue and Other Support

<table>
<thead>
<tr>
<th>Description</th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$186,179</td>
<td>$1,295,526</td>
<td>$1,481,705</td>
</tr>
<tr>
<td>Fundraising benefits income</td>
<td>259,476</td>
<td>259,476</td>
<td>259,476</td>
</tr>
<tr>
<td>Less: Direct benefit expenses</td>
<td>(80,112)</td>
<td>(80,112)</td>
<td>(80,112)</td>
</tr>
<tr>
<td>Donated artwork, goods and services</td>
<td>123,150</td>
<td>123,150</td>
<td>123,150</td>
</tr>
<tr>
<td>Art sales, net of cost of goods sold</td>
<td>4,375</td>
<td>4,375</td>
<td>4,375</td>
</tr>
<tr>
<td>Other income</td>
<td>21,452</td>
<td>21,452</td>
<td>21,452</td>
</tr>
<tr>
<td>Interest Income</td>
<td>1,056</td>
<td>612</td>
<td>1,668</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>1,826,382</td>
<td>(1,826,382)</td>
<td>1,668</td>
</tr>
<tr>
<td><strong>Total Revenue and Other Support</strong></td>
<td><strong>2,341,958</strong></td>
<td><strong>(530,244)</strong></td>
<td><strong>1,811,714</strong></td>
</tr>
</tbody>
</table>

#### Expenses

**Program Services**
- HIV Program: 640,329
- Hepatitis C Virus Program: 319,337
- TB/HIV Program: 1,127,736

**Total Program Services**: 2,087,402

**Supporting Services**
- Management and General: 262,119
- Fundraising: 163,942

**Total Expenses**: 2,513,463

**Increase (decrease) in net assets**: (171,505) (530,244) (701,749)

**Net assets, beginning of year, as previously reported**: 1,321,367 1,173,748 2,495,115

**Prior period adjustments**: 586,172 875,311 1,461,483

**Net assets, beginning of year, as restated**: 1,907,539 2,049,059 3,956,598

**Net Assets, End of Year**: $1,736,034 $1,518,815 $3,254,849

### Summary of 2018 Functional Expenses

- **Program Services**: 83%
- **Fundraising**: 7%
- **Management & Administration**: 10%
2018 TAG CONTRIBUTORS

$100,000 or more
The Aurum Institute
Elton John AIDS Foundation
Foundation for Innovative New Diagnostics
Bill and Melinda Gates Foundation
Stop TB Partnership
hosted by UNOPS
Veterans Affairs Medical Center of Washington, DC
ViivHealth

$50,000 to $99,999
Broadway Cares / Equity Fights AIDS
Ford Foundation
Nike, Inc.
Red Hot Organization

$25,000 to $49,999
Debs Foundation: Richard A. and Barbara Knowles
Debs, Nick Debs
Elizabeth Glaser Pediatric AIDS Foundation
Global Drug Facility via
Elizabeth Glaser Pediatric Foundation: Richard

$10,000 to $24,999
Joy A. Tomchin
M•A•C AIDS Fund
Ford Foundation

$5,000 to $9,999
Celeste B. Cooper
David Coryk
Monica Friell
Harvard University
Housing Works / Charles King and Matthew Bernardo
Barbara F. Hughes
Noel E.D. Kirnon and Monica Friel
The Elizabeth Taylor AIDS Foundation

$1,000 to $2,499
AIDS Fonds Netherlands
Kim Allen-Niesen
Anonymous donations
AVAC / Mitchell Warren
Ian Bailey / Vivid Coffee
Margot and Robert J. Bazell
Michael Beltran and Timothy Ford
Jonathan Binstock
Andrew Bonacina
Bob Bronzo
Maria Bulanoyarova / Gay Arts Foundation
Kenneth G. Castro, MD
Paul Cosso
Dick Dadey
Ariane Z. Dar / New Ground Fund of Marine
Community Foundation
Nick Delacorte
Florence Derieux
John Deelyng
Courtney E. DiMartino
Hon. Thomas K. Duane
Joseph Dunning
David France in memory of Tim McCarthy
Garance Franke-Ruta
Barbara Gamson
Robert Gillard and James Harrington in honor of Monte Steinman
Global Health Strategies
Judy and Steven Glick
Ron Goldberg and Joe Chiplock
Karen and Steve Hirdt
David Hochberg
Foundation
Hon. James C. Hormel
Tim Messing and Audrey Sokoloff in memory of Richard Lynn and Joseph Evall
IAVI / Dr. Marc Feinberg
Johns Hopkins University
JPMorgan Chase Bank
M. Ash III
Emmy Kondo in memory of Paul Corser
Babette Krolik and Sara Rafsky in memory of Bob Rafsky
Winston B. Layne
Josh Layger and Jeffrey Seller Family
The Lesbian, Gay, Bisexual and Transgender Community Center
Michael K. Longacre
Medecins Sans Frontieres
Mirta and George Morris
Sally Morrison and Tobias Corser
Jason Oscher and Richard Schuble in memory of Margie Garber-Steinman
GlucoTek/L backpacks
Partners In Health
Public Citizen Foundation
Karen Bronzo Rabb and Jefferson Rabb
Lance Renner
Daniel Schaefer
Andreas Schirmeister in honor of Monte Steinman
Evans Schwartz and Robert Fitterman
Elizabith Sherman
Scott Stangenes
Monte Steinman
Amandostefi Mitnick
Madeline Warren
Susan Withrow
Suzanne Zissu
Alain and Elsa Bankier
“Monte Steinman does a great job for you!!”
Jack Battaglia
Prof. Richard M. Buxbaum and Catherine B. Hartshorn in honor of Mark Harrington
Paula and Mitchell Chalfin
Ellen Chesler in honor of Jeff Mendoza
Steven M. and Denise Chickery
Stephanie and Walter Cowles
Paul L. Dietz
Steven M. Frank and Dr. Elizabeth Powell
Andrew Friedman
Jennifer J. Furin, MD, PhD
New York State Assemblymember
Deborah J. Glick
Aaron Glick
Roy M. “Trip” Gulick, MD
Robert C. Henry
Michelle and Andre Doré
/ The InLink Group
Rebecca Jordan-Young in honor of Sally C. Cooper
Burt Lazarin
David C. Levine
Chris Lirapi
Loring McAlpin
Joseph McConnell and Erik Haagensen
Jeff Mendoza
Albert S. Messina in honor of Richard Jacobs
Mount Sinai Institute for Advanced Medicine
Daniel Pracek
Clifford Richner
Walter Rieman in memory of Tom Stoddard
Greig Sargeant
Jeffrey H. Schmitt and Dr. Michael A. Petrilli, DDS, MPH
Sarah F. and Roy E. Schutzenegel in memory of Harty Fleischmann
Screen Engine/ASI
David Shaw in honor of Bob Bronzo
Ginny Shubert and David Sipress
Jane Silver in honor of Peggy Hamburg
Peter Staley
Marc Szafran
Dan Tietz / Bailey House
Barbara Toll in honor of Jeff Mendoza
Robert Wheeler
James M. and Ruth E. Wilder Foundation

$500 to $999
Abramson Tzedakah Fund
/Murray A. Abrams
Peter L. Allen in honor of Bruce Schackman

$250 to $499
AIDS Treatment Activists Coalition
Marc J. Berman
Scott P. Campbell
Richard Cardillo in memory of Peter F. Diffly Jr.
Dr. Charles C.J. Carpenter Jr. and Mrs. Sally F. Carpenter
Jeanie Carstensen
Lawrence Chanen
Mathew Chappell in memory of Spencer Cox
Deborah Cotton, MD, in honor of Ida May Lipsett
Megan Harrington and Jonathan Creight on in memory of Jay Kevin Funk
Scott Dainton
Judith C. Davis-Fagan
Peter Morris Dixon
Monica Gerber
Leslie Asako Gladsjo
Edward B. Parran and James F. Guidera
Paula Hartstein and Jonathan Levin in honor of Eric Lessin
Larry Iannotti in honor of Richard Lynn and Joseph Evall
Karyn Kaplan
Jason Lamb and Dr. Alan Kristal
Margaret Lenion
Linda Liedtka
Massachusetts Medical Society on behalf of Dr. Helen Cox and Dr. Val Mizrahi
Merle C. McCann, MD
Elaine and Gunn Mealy
Peterando J. Alva Mirá
Scott Newman
Kathleen O’Leary in honor of Bob Bronzo
Pam A. Parker
Richard and Alice Pierson
Family Trust
Laura Pinksky in honor of GHAP
Christina Previti
Sheila Reves
David Rosen
Aditya Sankaranarayan
Peter Schamel
Dr. Jack Steever
Shivani Thaker
Keith S. Tobin, MD
Augusta Weiss
Elizabeth Strong Williams

plus donations from an additional 215 generous contributors.

We would also like to thank Zoe Leonard, Joy Episalla, Diagonal Media, King Displays, Print Positive NY and SpotCo for their generous in-kind donations of goods and services.
About TAG

Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.

TAG works to ensure that all people with HIV, TB, or HCV receive lifesaving treatment, care, and information.

We’re science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions.

TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end HIV, TB, and HCV.

Support TAG

TAG made many strides in the fight against HIV, HCV, and TB. We cannot lose momentum during this ever-changing political climate.

Make a gift to TAG and help us advocate for the needs of all people impacted by HIV, HCV, and TB.

Support TAG today: www.treatmentactiongroup.org/support.

Does your organization have a matching gifts program? Don’t miss your chance to make a gift that keeps on giving. Complete and send us your company’s matching gift form to double your contribution’s impact!

Thank You Board Officers

TAG’s staff and board congratulate our two new Board Officers: Vice President, Bobby McLain, and Secretary, Rob Lennon. They take their place alongside our long-time Board President, Barbara Hughes, and Treasurer, Laura Morrison. We thank all four of our Officers for their dedication and service, and Barbara, Bobby, Laura, and Rob: you have our sincere gratitude for jobs well done.

TAG Limited Art Editions

Each year at its Research in Action Awards, TAG presents a new, limited edition work of art. Past artists include Zoe Leonard, Erica Baum, Rosalind Fox Solomon, Joy Episalla, Kate Shepherd, Nan Goldin, Robert Gober, Bill Jacobson, fierce pussy, Donald Moffett, Tony Feher, Carrie Yamaoka, David Armstrong, and Richard Renaldi.

Joy Episalla, 2015, Celestial Bodies, (40° 44' N x 73° 59' W), 1

TAG retains an inventory of many of the editions for sale to the public, and all proceeds benefit TAG’s work. If you’re interested in purchasing an edition or learning more about the available editions, detailed information can be found at http://www.treatmentactiongroup.org/limited-art-editions.

Save the Date!
RESEARCH IN ACTION AWARDS
November 14, 2019
6 pm

2019 BOARD OF DIRECTORS

PRESIDENT: Barbara Hughes
VICE PRESIDENT: Bobby McLain
TREASURER: Laura Morrison
SECRETARY: Robert W. Lennon
Jim Aquino
Frank Bua
Dick Daday
Nick Debs
Joy Episalla
Kevin Goetz
Roy Gulick, M.D.
Jameel Jiwani
Richard Lynn, Ph.D., M.P.H.
Jeff Mendoza
Robert Monteleone
Eddie Pelto
David Sigal
Monte Steinman
Mrinal Vikram

STAFF
EXECUTIVE DIRECTOR:
Mark Harrington
DEPUTY EXECUTIVE DIRECTOR – PROGRAMS: Erica Lessem
DEVELOPMENT MANAGER:
Jean Dorak
TB PROJECT CO-DIRECTOR:
Mike Frick
STATE AND LOCAL POLICY DIRECTOR:
Annette Gaudino
HCV PROJECT DIRECTOR: Bryn Gay
FINANCE MANAGER:
Christopher George
DIRECTOR OF FINANCE AND OPERATIONS:
Sabrina Guerrero-Morris
BASIC SCIENCE, VACCINES, AND CURE PROJECT DIRECTOR:
Richard Jefferys
HIV PROJECT DIRECTOR:
Jeremiah Johnson
GOVERNMENT RELATIONS AND POLICY OFFICER:
Elizabeth Lovinger
U.S. AND GLOBAL HEALTH POLICY DIRECTOR: Suraj Madoori
ADMINISTRATOR:
Joseph McConnell
TB PROJECT CO-DIRECTOR:
Lindsay McKenna
COMMUNICATIONS MANAGER:
Dorrit Walsh